New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report.

ABSTRACT:

Introduction

Secukinumab is an anti-interleukin (IL)-17 used in the treatment of rheumatological conditions such as ankylosing spondylitis and psoriasis. Despite elevated IL-17A levels in inflammatory bowel disease (IBD) patients, clinical trials suggest IL-17 inhibition may exacerbate disease activity in IBD. Multiple sclerosis (MS) also has a suspected association with IBDs.

Case presentation

A 22-year-old man who has a paternal grandfather with a history of MS was started on secukinumab for suspected ankylosing spondylitis. Three months after secukinumab initiation, he developed new gastrointestinal (GI) symptoms and was diagnosed with ulcerative colitis. He responded to a course of corticosteroids, and his secukinumab was stopped. He remains in clinical and endoscopic re

SUBMITTER: Hagh-Doust H 

PROVIDER: S-EPMC12659643 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature